Form 4: Sangamo Therapeutics Officer Sells Shares for Tax

Sangamo Therapeutics' Principal Financial Officer, Prathyusha Duraibabu, reported a disposition of 36,676 shares of common stock for mandatory tax withholding purposes.

Summary

• Prathyusha Duraibabu, the Principal Financial Officer of Sangamo Therapeutics, Inc. (SGMO), reported a transaction on January 22, 2026.
• The transaction involved the disposition of 36,676 shares of common stock at a price of $0.3985 per share.
• This disposition was solely for mandatory tax withholding purposes upon the vesting of a restricted stock unit (RSU) grant, as per the Issuer's Amended and Restated 2018 Equity Incentive Plan.
• The transaction does not represent a discretionary trade by the Reporting Person.
• Following this transaction, Prathyusha Duraibabu beneficially owns 660,042 shares of common stock.
• The beneficially owned shares include 52,387 shares from the January 22, 2026 vesting installment of a January 22, 2024 RSU grant.
• Also included are 5,010 shares from a February 24, 2023 RSU grant, vesting in equal quarterly installments through February 24, 2026.
• Additionally, 120,000 shares from a February 25, 2025 RSU grant are included, with one-fourth vesting on February 25, 2026, and the remainder vesting in 8 successive equal quarterly installments.

Sentiment

Score: 5

Explanation: The filing reports a routine administrative transaction (tax withholding upon RSU vesting) which is neutral in sentiment and does not reflect a discretionary investment decision by the insider.

Future Outlook

Future vesting schedules for the Reporting Person's Restricted Stock Units include quarterly installments through February 24, 2026, for a February 24, 2023 grant, and a February 25, 2025 grant with one-fourth vesting on February 25, 2026, followed by 8 equal quarterly installments. All vesting is contingent on continuous service.

Management Comments

• The disposition of shares was solely for mandatory tax withholding purposes using the Issuer's closing stock price on January 22, 2026, of $0.3985/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan.
• This required tax withholding transaction is deemed to constitute a disposition of these shares to the Issuer for reporting purposes and does not represent a discretionary trade by the Reporting Person in the open market or otherwise.

Industry Context

NA

Stakeholder Impact

• Minimal direct impact on shareholders as this is a routine tax-related transaction, not a discretionary sale indicating a change in management's confidence or outlook.

Next Steps

• Continued vesting of the Reporting Person's February 24, 2023 RSU grant in successive equal quarterly installments through February 24, 2026.
• First vesting of one-fourth of the February 25, 2025 RSU grant on February 25, 2026, followed by 8 successive equal quarterly installments.

Key Dates

Recommendation

The filing details a routine insider transaction for tax withholding purposes upon RSU vesting. This administrative event does not reflect a discretionary investment decision by the officer and therefore provides no new fundamental information to alter an existing investment thesis. Investors should hold their position and look for more substantive company updates.

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, Tax Withholding, Equity Incentive Plan